Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete ...

Alecensa (alectinib) demonstrated a 22% reduction in the risk of death compared with Xalkori (crizotinib) in the frontline ...

Guard Therapeutics (publ) today announced top-line results from the company's Phase 2b POINTER study evaluating the investigational drug candidate RMC-035 as a kidney-protective therapy in patients un ...

A research trial spearheaded by Merck hopes to change that — and Franciscan Health Indianapolis is at the forefront too, as it is the only hospital in Indiana selected to take part in the ...

Ipilimumab plus nivolumab improved PFS over nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns. The combination showed higher overall response rates and a favorable safety profile ...

The ALPHAMEDIX-02 trial assessed 212Pb-DOTAMTATE in PRRT-naïve and PRRT-exposed GEP-NET patients, showing promising efficacy in both cohorts. PRRT-naïve patients exhibited a 60% response rate, while ...

A chef who was diagnosed with an aggressive form of breast cancer after discovering a lump is urging all men to “check their ...

All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile ...

Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 ...

Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label based on the Phase 3 ZENITH ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Canada Inc. announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for humanized ...

Novartis AG ( NYSE: NVS) M&A Call October 27, 2025 8:00 AM EDT ...